🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

875 results for “A.” Clear

  1. -, PARACETAMOL , CILAZAPRIL , Dapirolizumab pegol, EPINEPHRINE , DIPHENHYDRAMINE , -, -, -, -, -, -, -

    Pharma Mar S.A.

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  2. -, Rozanolixizumab

    Pharma Mar S.A.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. -, Rozanolixizumab

    Pharma Mar S.A.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. 0.9% Sodium Chloride for Injection, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  5. 64Cu(II)Cl2 solution for injection

    A.C.O.M. - Advanced Center Oncology

    Cancer on the prostatic bed

    phase 3 small molecule active

    1 trial

  6. 64Cu(II)Cl2 solution for injection, Fluorocolina (18F) Curium Italy 225 MBq/mL soluzione iniettabile

    A.C.O.M. - Advanced Center Oncology

    Prostate cancer at risk of developing metastatic lesions

    phase 3 small molecule active

    1 trial

  7. A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer's Disease Psychosis

    Pharma Mar S.A.

    Alzheimer's Disease Psychosis

    phase 3 other active

    1 trial

  8. A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

    Pharma Mar S.A.

    Lewy body Dementia psychosis (LBDP)

    phase 3 other active

    1 trial

  9. A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744

    GlaxoSmithKline Biologicals S.A.

    Severe asthma with an eosinophilic phenotype

    phase 3 other active

    1 trial

  10. A placebo matching Mepolizumab, Nucala 100 mg solution for injection in pre-filled syringe, A placebo matching Depemokimab, GSK3511294, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection, Nucala 100 mg solution for injection in pre-filled syringe, Fasenra 30 mg solution for injection in pre-filled syringe

    GlaxoSmithKline Biologicals S.A.

    Severe asthma with an eosinophilic phenotype

    phase 3 small molecule active

    1 trial

  11. ABIRATERONE, 177Lu-PNT2002, GALLIUM (68GA) GOZETOTIDE , ENZALUTAMIDE

    Pharma Mar S.A.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  12. ABO-102, ABO-102, ABO-102

    Pharma Mar S.A.

    Mucopolysaccharidosis type IIIA

    phase 3 small molecule active

    1 trial

  13. AMX0035, PL1 Oral powder in sachet, oral use

    Pharma Mar S.A.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 small molecule active

    1 trial

  14. APL-2

    Pharma Mar S.A.

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  15. ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Atenativ 1000 UI/20 ml polvere e solvente per soluzione per infusione endovenosa, Atenativ 50 NE/ml por és oldószer oldatos infúzióhoz vagy injekcióhoz, ATENATIV 1000 U.I., polvo y disolvente para solución para perfusión

    Pharma Mar S.A.

    Congenital antithrombin deficiency

    phase 3 small molecule active

    1 trial

  16. AZACITIDINE, Lisaftoclax, Dummy APG-2575 oral tablets, matching APG-2575 oral tablets. strength: 200 mg/tablet., AZACITIDINE

    Pharma Mar S.A.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  17. Abemaciclib, Lasofoxifene, Fulvestrant

    Pharma Mar S.A.

    Locally advanced or metastatic breast cancer

    phase 3 small molecule active

    1 trial

  18. Albutein 50 g/l solución para perfusión.

    Instituto Grifols S.A.

    Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization

    phase 3 small molecule active

    1 trial

  19. Amisulpride, DEXAMETHASONE PHOSPHATE, ONDANSETRON

    Pharma Mar S.A.

    post-operative nausea and vomiting in pediatric patients

    phase 3 small molecule active

    1 trial

  20. An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

    Pharma Mar S.A.

    Primary Hyperoxaluria

    phase 3 other active

    1 trial

  21. Angoron 150 mg/3 ml amp ενέσιμο διάλυμα, FLECARDIA Διάλυμα για ένεση/έχχυση

    Pharma Mar S.A.

    Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35%

    phase 3 small molecule active

    1 trial

  22. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  23. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  24. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources